Following the May 2023 Series D, ElevateBio announced a 13% workforce reduction and reduced some early preclinical work, focusing resources on BaseCamp manufacturing and the Life Edit gene-editing platform.
SourcePublic company, workplace, funding, and market signals
Updated Aug 16, 2026
ElevateBio is a technology-driven genetic-medicine company that combines proprietary gene-editing and cell-engineering technologies with end-to-end process development and cGMP manufacturing. It partners with biopharmaceutical companies from discovery through commercialization through its Life Edit and BaseCamp businesses.
Primary product
Integrated genetic-medicine platform: Life Edit gene-editing technologies and R&D plus BaseCamp process development and cGMP manufacturing services for cell therapies, gene therapies, viral vectors, mRNA, and related modalities.
Founded
2017
Headquarters
200 Smith Street, Waltham, Massachusetts 02451, United States
Team size
300-400; third-party sources have reported approximately 342 employees, while the company reported just under 400 after its March 2025 reduction.
Industry
Biotechnology and pharmaceutical manufacturing
Sub-industry
Cell and gene therapy CDMO; genetic-medicine technology platforms; gene editing
Offices
Business model
Stage
Series D; private, revenue-generating company
Total raised
$1.2B
Latest round
Series D · May 2023
Latest amount
$401M
May 2023 · AyurMaya Capital Management Fund, managed by Matrix Capital Management
Mar 2021 · Matrix Capital Management
Mar 2020 · The Invus Group
May 2019 · UBS Oncology Impact Fund
Leadership
Chief Executive Officer and Board Member
Bhakti Bhargava
Chief Financial Officer
Larry Lockwood
Chief Commercial Officer
Amy Pooler
Chief Scientific Officer
Michael Paglia
Chief Technology Officer
Catherine Hu
SVP, Corporate Affairs and Chief of Staff
Missy Kotchey
SVP, Head of People and Culture
Aaron Nudelman
SVP, Head of Intellectual Property
Executive Chairman, ElevateBio Board of Directors; Co-founder
Ger Brophy
Strategic Advisor and former Interim Chief Executive Officer
Founders
Mitchell Finer
Co-founder
Vikas Sinha
Co-founder; former Chief Financial Officer; Board Member
Investors
The company describes its culture as a community of explorers focused on discovery, technology, progress, and accelerating life-transforming therapies. Its careers materials emphasize cross-functional collaboration, continuous learning, and five culture principles, although the specific principles were not consistently exposed in search excerpts.
Visa sponsorship
Limited
Compensation
Public job postings provide role-specific ranges in some cases; one Pittsburgh quality internship listed $25 per hour. Public Department of Labor aggregation indicates a history of H-1B filings, with a reported median sponsored salary of approximately $95,000 and filings concentrated in Waltham and Durham. Glassdoor estimates compensation ranging from about $46,000 for manufacturing associates to approximately $303,000 for vice presidents, but these are third-party estimates rather than company-confirmed ranges.
Benefits
Pricing
Custom, program-specific pricing; public evidence indicates negotiated contracts for discovery, process development, technology transfer, cGMP manufacturing, licensing, milestones, royalties, and—in some partnerships—profit sharing. No public standard price list was found.
Differentiators
Technology
Customers
Competitors
Estimated revenue
Approximately $100M-$500M annually. CNBC reported $120M of 2024 revenue, while third-party company-data sources estimate approximately $437M; the discrepancy reflects limited private-company disclosure and differing methodologies.
Estimated monthly visits
25.5K
Traffic estimate as of Jun 2026
Following the May 2023 Series D, ElevateBio announced a 13% workforce reduction and reduced some early preclinical work, focusing resources on BaseCamp manufacturing and the Life Edit gene-editing platform.
SourceEndpoints News reported an additional workforce reduction of approximately 4% in October 2024, when the company had roughly 500 employees.
SourceThe company confirmed a further 17% workforce reduction, bringing employment to just under 400. Management cited biotech-sector headwinds, organizational simplification, and concentration on high-impact BaseCamp and Life Edit capabilities.
SourceElevateBio acquired genome-editing company Life Edit Therapeutics, formerly Beam Therapeutics' gene-editing unit, for an undisclosed amount. Life Edit is now a core ElevateBio business.
SourceFounder and long-serving CEO David Hallal transitioned to Executive Chairman; Vikas Sinha stepped down as CFO and Bhakti Bhargava became CFO. Ger Brophy subsequently served as interim CEO before Christopher Murphy became CEO in January 2026.
SourceElevateBio · Jan 2026
The company reported a sixth consecutive year of revenue growth, 18 supported preclinical and clinical programs, a 98% manufacturing batch-success rate, a 30% expansion of Waltham manufacturing capacity, and continued construction of BaseCamp Pittsburgh.
ElevateBio · Jan 2026
Christopher Murphy became CEO, succeeding interim CEO Ger Brophy. Brophy remains an advisor on strategy and technology.
ElevateBio · Aug 2025
BaseCamp Waltham became the first genetic-medicine manufacturing business reported to have ICMC certification across viral gene delivery, nonviral gene delivery, and cell-therapy products.
Fierce Biotech · Mar 2025
ElevateBio confirmed a 17% workforce reduction, its third reported reduction since 2023, citing organizational simplification and prioritization of BaseCamp and Life Edit.
ElevateBio · Mar 2025
ElevateBio and AWS announced a multi-year collaboration using AWS cloud infrastructure, SageMaker, protein-language models, and Life Edit data to accelerate discovery and optimization of CRISPR systems.
13 jobs at ElevateBio